Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial

JACC: Cardiovascular Interventions

Volumn 9, Issue 18, 2016, Pages 1905-1913

  Abtan, Jérémie ^a   Steg, P Gabriel ^a,b   Stone, Gregg W ^c   Mahaffey, Kenneth W ^d   Gibson, C Michael ^e   Hamm, Christian W ^f   Price, Matthew J ^g   Abnousi, Freddy ^g   Prats, Jayne ^h   Deliargyris, Efthymios N ^h   White, Harvey D ⁱ   Harrington, Robert A ^d   Bhatt, Deepak L ^j  

^a BICHAT HOSPITAL   (France)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c Department of Medicine   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Kerckhoff Heart and Thorax Center   (Germany)

^g SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^h MEDICINES COMPANY   (United States)

ⁱ UNIVERSITY OF AUCKLAND   (New Zealand)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

ACS; Cangrelor; CHAMPION PHOENIX; PCI; stable angina

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; PLACEBO; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANGINA, STABLE; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY THROMBOSIS; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; ODDS RATIO; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE MONOPHOSPHATE; AGED; ANGINA, STABLE; CHI-SQUARE DISTRIBUTION; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84988914883     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.06.046     Document Type: Article

References (33)

1. 1 Steinhubl, S.R., Berger, P.B., Mann, J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002), 2411–2420.
2. 2 Mehta, S.R., Yusuf, S., Peters, R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001), 527–533.
3. 3 Bhatt, D.L., Hulot, J.-S., Moliterno, D.J., Harrington, R.A., Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res 114 (2014), 1929–1943.
4. 4 Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
5. 5 Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
6. 6 Vranckx, P., Kalesan, B., Stefanini, G.G., et al. Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. EuroIntervention 11 (2015), 171–179.
7. 7 Alexopoulos, D., Galati, A., Xanthopoulou, I., et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60 (2012), 193–199.
8. 8 Ibrahim, K., Christoph, M., Schmeinck, S., et al. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 85 (2014), 649–656.
9. 9 Bhatt, D.L., Stone, G.W., Mahaffey, K.W., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368 (2013), 1303–1313.
10. 10 Bhatt, D.L., Lincoff, A.M., Gibson, C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361 (2009), 2330–2341.
11. 11 Harrington, R.A., Stone, G.W., McNulty, S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361 (2009), 2318–2329.
12. 12 Steg, P.G., Bhatt, D.L., Hamm, C.W., et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 382 (2013), 1981–1992.
13. 13 Spoon, D.B., Psaltis, P.J., Singh, M., et al. Trends in cause of death after percutaneous coronary intervention. Circulation 129 (2014), 1286–1294.
14. 14 Daly, C.A., De Stavola, B., Sendon, J.L.L., et al. Predicting prognosis in stable angina–results from the Euro heart survey of stable angina: prospective observational study. BMJ 332 (2006), 262–267.
15. 15 Mandelzweig, L., Battler, A., Boyko, V., et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 27 (2006), 2285–2293.
16. 16 Leonardi, S., Mahaffey, K.W., White, H.D., et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J 163 (2012), 768–776.e2.
17. 17 Thygesen, K., Alpert, J.S., White, H.D., Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 28 (2007), 2525–2538.
18. 18 Jatene, T., Harrington, R., Stone, G., et al. Investigator-reported bleeding versus unblinded post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX Trial. J Am Coll Cardiol 67 (2016), 596–598.
19. 19 Jaffe, A.S., Lindahl, B., Katus, H.A., Sensitive troponin I assay in patients with suspected acute coronary syndrome. JAMA 306 (2011), 488–489.
20. 20 Task Force on the Management of ST-segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC), Steg, P.G., James, S.K., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 33 (2012), 2569–2619.
21. 21 Authors/Task Force Members, Hamm, C.W., Bassand, J.P., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32 (2011), 2999–3054.
22. 22 Montalescot, G., Bolognese, L., Dudek, D., et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369 (2013), 999–1010.
23. 23 Bellemain-Appaix, A., O'Connor, S.A., Silvain, J., et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 308 (2012), 2507–2516.
24. 24 Bellemain-Appaix, A., Kerneis, M., O'Connor, S.A., et al. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ, 349, 2014, g6269.
25. 25 Collet, J.-P., Silvain, J., Bellemain-Appaix, A., Montalescot, G., Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation 130 (2014), 1904–1914.
26. 26 Stone, G.W., Ware, J.H., Bertrand, M.E., et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 298 (2007), 2497–2506.
27. 27 Alexopoulos, D., Bhatt, D.L., Hamm, C.W., Steg, P.G., Stone, G.W., Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap. American Heart Journal 170 (2015), 3–12.
28. 28 Montalescot, G., van 't Hof, A.W., Lapostolle, F., et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371 (2014), 1016–1027.
29. 29 Iqbal, J., Sumaya, W., Tatman, V., et al. Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. EuroIntervention 9 (2013), 62–69.
30. 30 Fuchs, S., Stabile, E., Kinnaird, T.D., et al. Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications. Circulation 106 (2002), 86–91.
31. 31 Park, D.-W., Kim, Y.-H., Yun, S.-C., et al. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. Eur Heart J 34 (2013), 1662–1669.
32. 32 Trimarchi, S., Smith, D.E., Share, D., et al. Retroperitoneal hematoma after percutaneous coronary intervention: prevalence, risk factors, management, outcomes, and predictors of mortality: a report from the BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) registry. J Am Coll Cardiol Intv 3 (2010), 845–850.
33. 33 Fan, W., Plent, S., Prats, J., Deliargyris, E.N., Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol 117 (2016), 1439–1443.